NDAINJECTIONINJECTABLE
Approved
May 1984
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 12h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PRECEF (ceforanide) is an injectable second-generation cephalosporin antibiotic approved in 1984 for bacterial infections. It is administered via injection and works by inhibiting bacterial cell wall synthesis. The drug treats a range of aerobic and anaerobic infections in hospitalized patients.
LOE Approaching
As a legacy injectable antibiotic approaching loss of exclusivity with moderate competitive pressure, this product likely operates with a small, maintenance-focused commercial team.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on PRECEF offers limited upside for career growth, as the product operates at or near loss of exclusivity with no active development pipeline. Roles focus on defending institutional relationships, managing generic competition, and optimizing pricing in a mature market.
Field Sales Representative (Hospital/Institutional)Account Executive (Pharmacy/GPO)
Worked on PRECEF at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.